Contribute Try STAT+ Today

A controversial Trump administration plan to lower drug costs by pegging prices to what are paid by several foreign countries is getting pushback from dozens of groups. They argue the proposal would import price controls, restrict patient access, and reduce incentives for medical innovation.

In a letter to House and Senate leaders, the groups maintain the proposal is misguided and would ultimately hurt millions of Medicare B beneficiaries. And so, they urged the lawmakers to end the proposed pilot program and instead consider implementing some of the ideas in a limited fashion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.